Asymmetric synthesis of conformationally constrained Fingolimod analogues - Discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist

Journal of Medicinal Chemistry

Volumn 50, Issue 25, 2007, Pages 6428-6435

  Zhu, Ran ^a   Snyder, Ashley H ^b   Kharel, Yugesh ^b   Schaffter, Lisa ^c   Sun, Qin ^a   Kennedy, Perry C ^b   Lynch, Kevin R ^b   Macdonald, Timothy L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[1 AMINO 3 (4 OCTYLPHENYL)CYCLOPENTYL]METHANOL; [1 AMINO 3 (4 OCTYLPHENYL)CYCLOPENTYL]METHYL DIHYDROGEN PHOSPHATE; FINGOLIMOD; PHOSPHATASE; PHOSPHOTRANSFERASE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 3 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTEREOISOMER; DRUG MECHANISM; DRUG PURITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HYDROGENATION; HYDROPHOBICITY; LYMPHOCYTOPENIA; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RACEMIZATION; SINGLE DRUG DOSE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CALCIUM; CELL LINE; CRICETINAE; CRICETULUS; HUMANS; IMMUNOLOGIC FACTORS; MICE; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PRODRUGS; PROPYLENE GLYCOLS; RADIOLIGAND ASSAY; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 37049016039     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7010172     Document Type: Article

References (34)

1. Vezina, C.; Kudelski, A.; Sehgal, S. N. Rapamycin (AY-22,989), A New Antifungal Antibiotic. I. Taxonomy of the Producing Streptomycete and Isolation of the Active Principle. J. Antibiot. 1975, 28, 721-726.
2. Tanaka, H.; Kuroda, A.; Marusawa, H.; Hatanaka, H.; Kino, T.; Goto, T.; Hashimoto, M.; Taga, T. Structure of FK506, A Novel Immunosuppressant Isolated from Streptomyces. J. Am. Chem. Soc. 1987, 109, 5031-5033.
3. Halloran, P. F. Immunosuppressive Drugs for Kidney Transplantation. N. Engl. J. Med. 2004, 351, 2715-2729.
4. (a) Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y.; Okumoto, T. Fungal Metabolites. Part 11. A Potent Immunosuppressive Activity Found in Isaria sinclairii Metabolite. J. Antibiot. 1994, 47, 208-215.
5. (b) Adachi, K.; Kohara, T.; Nakao, N.; Arita, M.; Chiba, K.; Mishina, T.; Sasaki, S.; Fujita, T. Design, Synthesis, and Structure-Activity Relationships of 2-Substituted 2-Amino-1,3-propanediols: Discovery of a Novel Immunosuppressant, FTY720. Bioorg. Med. Chem. Lett. 1995, 5, 853-856.
6. Mandala, S.; Hajdu, R.; Bergstrom, J.; Quackenbush, E.; Xie, J.; Milligan, J.; Thornton, R.; Shei, G.-J.; Card, D.; Keohane, C.; Rosenbach, M.; Hale, J.; Lynch, C. L.; Rupprecht, K.; Parsons, W.; Rosen, H. Alteration of Lymphocyte Trafficking by Sphingosine 1-Phosphate Receptor Agonists. Science 2002, 296, 346-349.
7. Spiegel, S.; Milstien, S. Sphingosine 1-Phosphate: An Enigmatic Signalling Lipid. Nat. Rev. Mol. Cell Biol. 2003, 4, 397.
8. Albert, R.; Hinterding, K.; Brinkmann, V.; Guerini, D.; Muller-Hartwieg, C.; Knecht, H.; Simeon, C.; Streiff, M.; Wagner, T.; Welzenbach, K.; Zecri, F.; Zollinger, M.; Cooke, N.; Francotte, E. Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer. J. Med. Chem. 2005, 48, 5373-5377.
9. Hla, T.; Lee, M.-J.; Ancellin, N.; Paik, J. H.; Kluk, M. J. Lysophospholipids - Receptor Revelations. Science 2001, 294, 1875-1878.
10. Matloubian, M.; Lo, C. G.; Cinamon, G.; Lesneski, M. J.; Xu, Y.; Brinkmann, V.; Allende, M. L.; Proia, R. L.; Cyster, J. G. Lymphocyte Egress from Thymus and Peripheral Lymphoid Organs Is Dependent on S1P Receptor 1. Nature 2004, 427, 355-360.
11. 1 Antagonist in Vivo. Nat. Chem. Biol. 2006, 2, 434-441.
12. Pappu, R.; Schwab, S. R.; Cornelissen, I.; Pereira, J. P.; Regard, J. B.; Xu, Y.; Camerer, E.; Zheng, Y.-W.; Huang, Y.; Cyster, J. G.; Coughlin, S. R. Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine 1-Phosphate. Science 2007, 316, 295-298.
13. Forrest, M.; Sun, S. Y.; Hajdu, R.; Bergstrom, J.; Card, D.; Doherty, G.; Hale, J.; Keohane, C.; Meyers, C.; Milligan, J.; Mills, S.; Nomura, N.; Rosen, H.; Rosenbach, M.; Shei, G. J.; Singer, I. I.; Tian, M.; West, S.; White, V.; Xie, J.; Proia, R. L.; Mandala, S. Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes. J. Pharmacol. Exp. Ther. 2004, 309, 758-768.
14. 3 Receptor-Induced Reorganization of Epithelial Tight Junctions Compromises Lung Barrier Integrity and Is Potentiated by TNF. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9270-9275.
15. (a) Clemens, J. J.; Davis, M. D.; Lynch, K. R.; Macdonald, T. L. Synthesis of para-Alkyl Aryl Amide Analogues of Sphingosine 1-Phosphate: Discovery of Potent S1P Receptor Agonists. Bioorg. Med. Chem. Lett. 2003, 13, 3401-3404.
16. 1 Receptor Agonists. Bioorg. Med. Chem. Lett. 2005, 15, 3568-3572.
17. (c) Foss, F. W., Jr.; Snyder, A. H.; Davis, M. D.; Rouse, M.; Okusa, M. D.; Lynch, K. R.; Macdonald, T. L. Synthesis and Biological Evaluation of γ-Aminophosphonates as Potent, Subtype-Selective Sphingosine 1-Phosphate Receptor Agonists and Antagonists. Bioorg. Med. Chem. 2007, 15, 663-677.
18. Lynch, K. R.; Macdonald, T. L. Sphingosine 1-Phosphate Agonists Comprising Cycloalkanes and 5-Membered Heterocycles Substituted by Amino and Phenyl Groups. 2006-US5304 2006088944, 20060214, 2006.
19. Organ, M. G.; Murray, A. P. Ni-Catalyzed Cross Coupling of Alkoxide-Containing Vinyl Halides with Grignard Reagents. A "One-Pot" Synthesis of 2-[(Trimethylsilyl)methyl]-2-propen-l-yl Acetate. J. Org. Chem. 1997, 62, 1523-1526.
20. (a) Evans, D. A.; Britton, T. C.; Dorow, R. L.; Dellaria, J. F., Jr. Tetrahedron 1988, 44 (17), 5525-5540.
21. (b) Evans, D. A.; Ennis, M. D.; Mathre, D. J. J. Am. Chem. Soc. 1982, 104 (6), 1737-1739.
22. (c) Evans, D. A.; Ng, H. P.; Rieger, D. L. J. Am. Chem. Soc. 1993, 115 (24), 11446-11459.
23. Frederik Menges, A. P. Threonine-Derived Phosphinite-Oxazoline Ligands for the Ir-Catalyzed Enantioselective Hydrogenation. Adv. Synth. Catal. 2002, 344, 40-44.
24. Espino, C. G.; Du Bois, J. A. Rh-Catalyzed C-H Insertion Reaction for the Oxidative Conversion of Carbamates to Oxazolidinones. Angew. Chem., Int. Ed. 2001, 40 (3), 598-600.
25. Hinman, A.; Du Bois, J. J. Am. Chem. Soc. 2003, 125 (38), 11510-11511.
26. Davis, M. D.; Clemens, J. J.; Macdonald, T. L.; Lynch, K. R. Sphingosine 1-Phosphate Analogs as Receptor Antagonists. J. Biol. Chem. 2005, 280, 9833-9841.
27. Kharel, Y.; Lee, S.; Snyder, A. H.; Sheasley-O'Neill, S. L.; Morris, M. A.; Setiady, Y.; Zhu, R.; Zigler, M. A.; Burcin, T. L.; Ley, K.; Tung, K. S.; Engelhard, V. H.; Macdonald, T. L.; Pearson-White, S.; Lynch, K. R. Sphingosine Kinase 2 Is Required for Modulation of Lymphocyte Traffic by FTY720. J. Biol. Chem. 2005, 280, 36865-36872.
28. (a) Kiuchi, M.; Adachi, K.; Kohara, T.; Minoguchi, M.; Hanano, T.; Aoki, Y.; Mishina, T.; Arita, M.; Nakao, N.; Ohtsuki, M.; Hoshino, Y.; Teshima, K.; Chiba, K.; Sasaki, S.; Fujita, T. Synthesis and Immunosuppressive Activity of 2-Substituted 2-Aminopropane-1,3-diols and 2-Aminoethanols. J. Med. Chem. 2000, 43, 2946-2961.
29. (b) Hale, J. J.; Doherty, G.; Toth, L.; Li, Z.; Mills, S. G.; Hajdu, R.; Keohane, C. A.; Rosenbach, M.; Milligan, J.; Shei, G. J.; Chrebet, G.; Bergstrom, J.; Card, D.; Rosen, H.; Mandala, S. The Discovery of 3-(N-Alkyl)aminopropylphosphonic Acids as Potent S1P Receptor Agonists. Bioorg. Med. Chem. Lett. 2004, 14, 3495-3499.
30. (c) Hale, J. J.; Lynch, C. L.; Neway, W.; Mills, S. G.; Hajdu, R.; Keohane, C. A.; Rosenbach, M. J.; Milligan, J. A.; Shei, G. J.; Parent, S. A.; Chrebet, G.; Bergstrom, J.; Card, D.; Ferrer, M.; Hodder, P.; Strulovici, B.; Rosen, H.; Mandala, S. A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine 1-Phosphate-1 Receptor Agonists. J. Med. Chem. 2004, 47, 6662-6665.
31. (d) Hale, J. J.; Neway, W.; Mills, S. G.; Hajdu, R.; Keohane, C. A.; Rosenbach, M.; Milligan, J.; Shei, G. J.; Chrebet, G.; Bergstrom, J.; Card, D.; Koo, G. C.; Koprak, S. L.; Jackson, J. J.; Rosen, H.; Mandala, S. Potent S1P Receptor Agonists Replicate the Pharmacologic Actions of the Novel Immune Modulator FTY720. Bioorg. Med. Chem. Lett. 2004, 14, 3351-3355.
32. (e) Pan, S.; Mi, Y.; Pally, C.; Beerli, C.; Chen, A.; Guerini, D.; Hinterding, K.; Nuesslein-Hildesheim, B.; Tuntland, T.; Lefebvre, S.; Liu, Y.; Gao, W.; Chu, A.; Brinkmann, V.; Bruns, C.; Streiff, M.; Cannet, C.; Cooke, N.; Gray, N. A Monoselective Sphingosine 1-Phosphate Receptor-1 Agonist Prevents Allograft Rejection in a Stringent Rat Heart Transplantation Model. Chem. Biol. 2006, 13, 1227-1234.
33. Hale, J. J.; Yan, L.; Neway, W. E.; Hajdu, R.; Bergstrom, J. D.; Milligan, J. A.; Shei, G. J.; Chrebet, G. L.; Thornton, R. A.; Card, D.; Rosenbach, M.; HughRosen; Mandala, S. Synthesis, Stereochemical Determination and Biochemical Characterization of the Enantiomeric Phosphate Esters of the Novel Immunosuppressive Agent FTY720. Bioorg. Med. Chem. 2004, 12, 4803-4807.
34. Koide, Y.; Uemoto, K.; Hasegawa, T.; Sada, T.; Murakami, A.; Takasugi, H.; Sakurai, A.; Mochizuki, N.; Takahashi, A.; Nishida, A. Pharmacophore-Based Design of Sphingosine 1-Phosphate-3 Receptor Antagonists That Include a 3,4-Dialkoxybenzophenone Scaffold. J. Med. Chem. 2007, 50, 442-454.